Oral GLP-1 Revolution: Novo Nordisk's $149 Wegovy Pill Opens New Front in $150 Billion Obesity Drug War
Novo Nordisk launches oral Wegovy at $149/month as FDA approval of Eli Lilly's competing pill looms, potentially reshaping a market projected to reach $150 billion annually.